Printer Friendly

THERAGENICS ACHIEVES RECORD REVENUES AND EARNINGS FOR FIRST QUARTER OF 1992

 THERAGENICS ACHIEVES RECORD REVENUES AND EARNINGS
 FOR FIRST QUARTER OF 1992
 ATLANTA, April 14 /PRNewswire/ -- Theragenics Corp. (NASDAQ: THRX), an Atlanta-based cancer therapy company, announced today that, for the first quarter ended March 31, 1992, it achieved a record profit from continuing operations of $505,000, or 5 cents per share, compared to $30,000, or zero cents per share, compiled in the first quarter of 1991. The first quarter of 1991 also included a one-time licensing fee of $300,000, which yielded a one-time additional profit of $292,000.
 Theragenics' revenue from continuing operations for the first quarter of 1992 was a record $1,204,000, a 149 percent improvement over the $484,000 in revenue from continuing operations achieved during the same period last year.
 The 1992 first quarter was Theragenics' fifth consecutive profitable three-month span. During the quarter, the company's earnings from its TheraSeed implant therapy surpassed its earnings from that therapy for the entire year of 1991.
 TheraSeed is a non-surgical, outpatient treatment which uses implanted Palladium 103 seeds to eradicate prostate cancer.
 President and CEO John V. Herndon said, "Track records in small companies are extremely important to investors and the medical marketplace's acceptance of a new product or technology. The first quarter of 1992 is another indicator of our progress with TheraSeed in achieving those goals."
 Prostate cancer is the second most common and fatal cancer among men, afflicting an estimated 130,000 and killing 30,000 Americans last year.
 THERAGENICS CORP.
 Consolidated Statement of Operations
 (Unaudited)
 Three months ended March 31 1992 1991
 Revenues $1,204,000 $784,000(A)
 Net earnings 505,000 322,000(B)
 Earnings per common share $.05 $.03
 (A) -- Includes a one-time licensing fee of $300,000.
 (B) -- Includes a one-time licensing profit of $292,000.
 -0- 4/14/92
 /CONTACT: Bruce Smith, CFO of Theragenics, 404-381-8338, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics/
 (THRX) CO: Theragenics Corp. ST: Georgia IN: HEA SU: ERN


SH-CK -- NY028 -- 8187 04/14/92 10:54 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 14, 1992
Words:337
Previous Article:CME EMERGENCY MARKET CLOSING AT NOON CDT TODAY
Next Article:GTE REPORTS FIRST-QUARTER NET INCOME OF $427 MILLION VS. $197 MILLION A YEAR AGO; EXCLUDING A ONE-TIME CHARGE IN 1991


Related Articles
THERAGENICS RECORDS THIRD CONSECUTIVE PROFITABLE QUARTER; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS REVENUE 120 PERCENT
THERAGENICS RECORDS RECORD FOURTH QUARTER AND YEAR END RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 227 PERCENT
THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS; QUARTERLY PROFITS INCREASE NEARLY THREE-FOLD; REVENUES ALSO SOAR
THERAGENICS ANNOUNCES 1992 RESULTS; SALES INCREASE 58 PERCENT AND PROFITS DOUBLE; 1993 FORECAST SHOWS PROFITS UP 167 PERCENT
THERAGENICS REPORTS REVENUES AND EARNINGS FOR FIRST QUARTER OF 1993
THERAGENICS ANNOUNCES SECOND QUARTER RESULTS
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS
THERAGENICS ANNOUNCES 1993 RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters